Skip to main content

Table 3 Incidence of treatment-related adverse events

From: Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Any-grade in ≥ 5% of patients or any grade 3 TRAEs N = 51
Any grade
n (%)
Grade 3
n (%)
Patients with ≥1 event 39 (76.5) 4 (7.8)
Infusion-related reaction 15 (29.4) 0
Fatigue 9 (17.6) 0
Chills 6 (11.8) 0
Diarrhea 5 (9.8) 0
Dysgeusia 4 (7.8) 0
Pyrexia 4 (7.8) 0
Aspartate aminotransferase increased 3 (5.9) 0
Dry mouth 3 (5.9) 0
Nausea 2 (3.9) 1 (2.0)
Gamma-glutamyltransferase increased 1 (2.0) 1 (2.0)
Hypokalemia 1 (2.0) 1 (2.0)
Lipase increased 1 (2.0) 1 (2.0)
All immune-related TRAEs
Patients with ≥1 event 5 (9.8) 0
Hypothyroidism 2 (3.9) 0
Pneumonitis 2 (3.9) 0
Hyperthyroidism 1 (2.0) 0
Sarcoidosis 1 (2.0) 0
Vitiligo 1 (2.0) 0